UNA

RNAi drugs startup Arcturus Therapeutics this week announced that it has raised $5 million in a Series A round of financing, which comes just months after the company pulled in $1.5 million in seed money.

Startup Arcturus Therapeutics this week announced that it has acquired Marina Biotech’s unlocked nucleobase analog intellectual property in a move the company said would give it freedom to operate in the RNAi drugs space.

Tekmira Pharmaceuticals last week announced that it has acquired a worldwide, non-exclusive license to Marina Biotech's unlocked nucleobase analog technology, which is used to design RNAi payloads.

Marina Biotech this week announced that the Intellectual Property Office of New Zealand said it will grant the company a patent covering its unlocked nucleobase analog technology.

"We've established the intellectual property portfolio and basis to be an integrated personalized medicine company focused in nucleic acid therapeutics and diagnostics," President and CEO Michael French told Gene Silencing News.

Under the new arrangement, MDRNA is no longer obligated to make any future payments to RiboTask, which retains the rights to make, sell, and sublicense the UNA technology for research and diagnostic purposes.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.